New "in Vitro" Diagnostic Test for Oral Malodour (Striptest)

October 1, 2012 updated by: Marc Quirynen, Universitaire Ziekenhuizen KU Leuven

New "in Vitro" Diagnostic Test for Oral Malodour: First Prototype Evaluation

This study will assess the ability of a first prototype (strip) of a new chair side test to detect oral malodour. The strip is based on a new enzymatic reaction able to detect amines in saliva. Previous studies already showed significant correlations between oral malodor and the levels of amines in saliva. The limitation in their use as markers of oral malodour is the fact that the detection is usually carried out by complex techniques (High Performance Liquid Chromatography(HPLC)and Solid-Phase Micro Extraction-Gas Chromatography/Mass Spectrometry (SPME-GC/MS)). The results of the new enzymatic reaction can be evaluated by means of a colorimetric scale without necessity of extra apparatus.

The study will be carried out with volunteers recruited at a multidisciplinary consultation for bad breath, organized at the University Hospital Leuven, Belgium.

The paper strip will be used before the routine evaluation (organoleptic score (OS), the gold standard method for the diagnosis of halitosis and the level of volatile sulphur compounds (VSC), the most used adjunct tool to diagnose halitosis).

The results of the new chair side test (strip) will be correlated with the OS and VSC measurements (OralChroma™, Halimeter®). The sensitivity, specificity and positive and negative predicted values of the new chair side test will be calculated. The cut-off values for a yes/no test will be determined. The meaning of color scores will be analyzed to assign a meaningful outcome to each score with relation to odor intensity.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Leuven, Belgium, 3000
        • Recruiting
        • Department of Periodontology, Faculty of Dentistry, Catholic University of Leuven
        • Sub-Investigator:
          • Jesica Dadamio, Master Bioch
        • Principal Investigator:
          • Marc Quirynen, PhD, DDS
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Hundred consecutive adult subjects consulting the bad breath clinic who meet the inclusion criteria.

Number of volunteers extended to 150 in March 2012 (Amendment Research Agreement)

Description

Inclusion Criteria:

  • Adults (≥18 years
  • With no evidence of bad breath or bad breath of intra-oral cause (oral malodour)
  • Non-smokers or smokers from whom the organoleptic evaluation can be performed (no interference from smoke odour)

Exclusion Criteria:

  • Smokers from whom the organoleptic evaluation can not be performed because of interference from smoke odour
  • Presence of active caries
  • Presence of sinusitis or any other Oro-pharyngeal problem
  • On medications which can cause malodour
  • Reduced salivary flow due to pathological reasons (e.g. Sjögren syndrome)
  • Any oral pathophysiological condition or any oral disease (e.g. oral cancer, mucositis)
  • Pregnancy and nursing
  • Situation considered not compatible with the study according to the investigator's opinion; the latter includes: persons under homeopathic therapy, patients who used antibiotics during the 2 months before the study, patients frequently using chewing gum, patients under corticosteroids or other serious medications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy adults
Subjects consulting a bad breath clinic at the Department of Periodontology, KULeuven
Colour evaluation of a strip
Other Names:
  • Strip tes for oral malodour GABA (still confidential)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Colour evaluation of the new chair side test
Time Frame: Once (during the first consult to the clinic)
The colour will be assessed before all the other test and after 4 minutes of contact between the strip and the saliva of the volunteer.
Once (during the first consult to the clinic)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Organoleptic evaluation (OS)
Time Frame: Once (during the first consult to the clinic)
The OS will be determined by a trained and calibrated judge as described in the literature. Briefly, patients will be asked to count from one to eleven and the judge rated the exhaled air on a 0 to 5 score ( 0 represents absence of odour, 1 is given for barely noticeable odour, 2 for slight malodor, 3 for moderate malodor, 4 for strong malodor and 5 for severe malodor). The judge will also evaluate nasal breath in order to exclude extra-oral causes of halitosis and the odor of a sample of the tongue coating, if present.
Once (during the first consult to the clinic)
Total VSC reading
Time Frame: Once (during the first consult to the clinic)
The global concentration of sulphur containing compounds will be measured using a portable breath analyzer (Halimeter®, Interscan cooperation, Chatsworth, US. The maximum level attained (ppb) is determined by direct readings from the analog scale of the monitor.
Once (during the first consult to the clinic)
Specific VSC readings
Time Frame: Once (during the first consult to the clinic)
Hydrogen sulphide, methyl mercaptan and dimethyl sulphide will be measured using a commercially available system (OralChroma™, Abilit Corporation; Osaka City, Japan). This portable gas chromatograph is equipped with an indium oxide semiconductor gas sensor. The concentration values (ppbv) of the three gases will be recorded.
Once (during the first consult to the clinic)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Marc Quirynen, PhD, DDS, Universitaire Ziekenhuizen KU Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Anticipated)

December 1, 2012

Study Completion (Anticipated)

March 1, 2013

Study Registration Dates

First Submitted

October 12, 2010

First Submitted That Met QC Criteria

October 21, 2010

First Posted (Estimate)

October 22, 2010

Study Record Updates

Last Update Posted (Estimate)

October 2, 2012

Last Update Submitted That Met QC Criteria

October 1, 2012

Last Verified

October 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20100914

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Halitosis

Clinical Trials on In vitro chair side test

Subscribe